BACKGROUND: Allergic rhinitis (AR) is characterized by T helper 2 polarized immune response. The soluble HLA-G (sHLA-G) molecule has an immunomodulatory activity. However, so far, no study has investigated this activity in perennial AR (PAR). OBJECTIVE: The aim of this study was to evaluate serum sHLA-G levels in PAR patients and in a group of healthy controls. METHODS: Twenty-five PAR patients were enrolled. A group of 50 healthy non-allergic subjects was considered as control. sHLA-G serum levels were determined by immunoenzymatic method. RESULTS: Allergic patients had significantly higher levels of the sHLA-G (p < 0.001) molecule than normal controls. Moreover, there was a very strong correlation between sHLA-G and symptom severity and drug use (r = 0.85 and 0.793, respectively). CONCLUSION: The present study provides first evidence that serum sHLA-G levels are significantly increased in PAR patients. Moreover, sHLA-G might be considered as a biomarker for assessing clinical severity. Copyright 2009 S. Karger AG, Basel.
BACKGROUND:Allergic rhinitis (AR) is characterized by T helper 2 polarized immune response. The soluble HLA-G (sHLA-G) molecule has an immunomodulatory activity. However, so far, no study has investigated this activity in perennial AR (PAR). OBJECTIVE: The aim of this study was to evaluate serum sHLA-G levels in PAR patients and in a group of healthy controls. METHODS: Twenty-five PAR patients were enrolled. A group of 50 healthy non-allergic subjects was considered as control. sHLA-G serum levels were determined by immunoenzymatic method. RESULTS: Allergic patients had significantly higher levels of the sHLA-G (p < 0.001) molecule than normal controls. Moreover, there was a very strong correlation between sHLA-G and symptom severity and drug use (r = 0.85 and 0.793, respectively). CONCLUSION: The present study provides first evidence that serum sHLA-G levels are significantly increased in PAR patients. Moreover, sHLA-G might be considered as a biomarker for assessing clinical severity. Copyright 2009 S. Karger AG, Basel.
Authors: Giuseppe Murdaca; Paola Contini; Simone Negrini; Giorgio Ciprandi; Francesco Puppo Journal: J Immunol Res Date: 2016-06-20 Impact factor: 4.818